Abstract: Ilex asprella is routinely used in China as a traditional medicinal herb to treat influenza (Flu). However, its specific antiviral activity and underlying molecular mechanism have not yet been determined. In this study, we sought to determine the antiviral activity and mechanism of Asprellcosides B, an active component extracted from Ilex asprella, against the influenza A virus in cell culture. We also performed computer-assisted structural modeling and surface plasmon resonance (SPR) experiments to determine the viral target. Results show that Asprellcosides B reduced virus replication by up to 63% with an $\text{IC}_{50}$ of about $9\ \mu\text{M}$. It also decreased low pH-induced and virus-mediated hemolysis by 71% in vitro. Molecular docking simulation suggested binding to hemagglutinin (HA), confirmed by SPR assay. Altogether, our findings demonstrate that Asprellcosides B inhibits influenza A virus through specific binding to HA, resulting in the blockade of HA-mediated membrane fusion.
Introduction
Influenza remains a persistent global health threat, necessitating the development of diverse antiviral strategies. Currently, the primary defenses are M2 ion channel blockers and neuraminidase (NA) inhibitors like Oseltamivir. However, the rapid emergence of drug-resistant mutants has created an urgent need for "entry inhibitors" that target different stages of the viral lifecycle. While the herb Ilex asprella has long been used in traditional Chinese medicine to treat respiratory infections, the specific molecules responsible for its efficacy remained unidentified until this investigation into Asprellcosides B.
Methodology
The researchers employed a multidisciplinary approach to isolate and characterize the compound. Pure Asprellcosides B was extracted from Ilex asprella using a combination of macroporous resin, column chromatography (Sephadex LH-20, silica gel), and HPLC. Its structure was rigorously confirmed via NMR and IR spectroscopy.
To determine the compound's mechanism, the team conducted "time-of-addition" experiments using various medication modes (prophylactic, simultaneous, and therapeutic) to pinpoint which stage of the viral lifecycle was affected. These assays were performed against multiple IAV strains, including H1N1, H3N2, and H9N2, in A549 and MDCK cell cultures.
Key Results and Antiviral Potency
Asprellcosides B demonstrated significant antiviral activity across all tested IAV strains. In prophylactic tests, the compound inhibited viral replication by up to 63%, achieving an $\text{IC}_{50}$ of $8.87\ \mu\text{M}$. Notably, the compound exhibited a high safety profile in human lung cells (A549), with a $\text{TC}_{50} > 250\ \mu\text{M}$, yielding a Selection Index (SI) of over 28.
Biophysical assays further validated these findings. Surface Plasmon Resonance (SPR) analysis confirmed a strong physical interaction with the HA protein, showing a dissociation constant ($\text{K}_{\text{D}}$) of $7.44\ \mu\text{M}$. Furthermore, the compound decreased virus-mediated hemolysis—a proxy for membrane fusion—by 71% at low pH levels.
Mechanistic Insights
Unlike Oseltamivir, which prevents the release of new virions, Asprellcosides B acts as an entry inhibitor. Molecular docking simulations suggested that the compound binds to a hydrophobic pocket in the HA2 subunit of the viral hemagglutinin. This subunit acts as a "fusion machine" that pulls viral and host membranes together. By binding here, Asprellcosides B prevents the conformational changes required for fusion. This mechanism appears highly specific to the influenza virus architecture, as the compound showed no inhibitory effect against Zika, Dengue, or Herpes Simplex viruses.
Conclusion and Future Directions
This study identifies Asprellcosides B as a promising lead for a new class of influenza entry inhibitors. While its potency and safety margin are encouraging, the compound's low water solubility ($1.66\ \mu\text{g/mL}$) remains a hurdle for clinical application. Future work will focus on medicinal chemistry to improve its bioavailability and conducting in vivo animal studies to evaluate its therapeutic potential in complex biological systems.
Summary updated